VMAT2 inhibitors
- Reduce presynaptic monoamine packaging
- Valbenazine/deutetrabenazine: tardive dyskinesia
- Deutetrabenazine also treats Huntington chorea
- Akathisia/parkinsonism can occur
- Depression warning matters in Huntington disease
- CYP2D6 affects exposure for some agents
- Treat movements; they do not remove the cause
Class at a glance
- Reduce presynaptic monoamine packaging
Pharmacology
- CYP2D6 affects exposure for some agents
Clinical role
- Valbenazine/deutetrabenazine: tardive dyskinesia
- Deutetrabenazine also treats Huntington chorea
- Akathisia/parkinsonism can occur
- Treat movements; they do not remove the cause
Members / distinctions
- Depression warning matters in Huntington disease
Self-check
- What do VMAT2 inhibitors primarily reduce?
presynaptic monoamine packaging.
- What key adverse effect/risk occurs with VMAT2 inhibitors?
Akathisia/parkinsonism can occur.
Drugs in this class (5)
All drug classes · Open the interactive console ↗
![[+]-α-HTBZ ballicule — decagon mechanism diagram](/thumbs/plus_alpha_htbz.webp)